The Bottom Line Peptides are often too pricey
I wish I had tried it sooner instead of suffering through those two years
77 Likewise, MuSCs with higher levels of CD34 expression exhibit reduced differentiation propensity and are preferentially depleted with aging
Ultomiris (ravulizumab-cwvz) Indication(s): Multiple rare, complement-mediated disorders, including paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), neuromyelitis optica spectrum disorder (NMOSD) Manufacturer(s): Alexion/AstraZeneca 2024 Sales: $3.92 billion Why it sold so well: Ultomiris, developed by Alexion, AstraZeneca Rare Disease, is emerging as a hematology drug to watch in 2025, driven by strong commercial momentum and expanding clinical uptake in 2024
The classical triad of dysmenorrhea, dyspareunia, and dyschezia occurs in approximately 60% of patients but may not be present early in the disease course (Guo & Wang, 2006)
